Share on StockTwits

Cytomedix (NASDAQ:CMXI) CFO Steven A. Shallcross purchased 52,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was purchased at an average cost of $0.39 per share, for a total transaction of $20,280.00. Following the completion of the acquisition, the chief financial officer now directly owns 52,000 shares in the company, valued at approximately $20,280. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Cytomedix (NASDAQ:CMXI) traded down 3.50% during mid-day trading on Friday, hitting $0.386. The stock had a trading volume of 126,400 shares. Cytomedix has a 1-year low of $0.33 and a 1-year high of $0.68. The stock’s 50-day moving average is $0.39 and its 200-day moving average is $0.47. The company’s market cap is $48.0 million.

Cytomedix, Inc is a United States-based company that develops biologically active regenerative therapies for wound and tissue repair.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.